218 related articles for article (PubMed ID: 34815782)
1. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.
Chandrasekaran AP; Kaushal K; Park CH; Kim KS; Ramakrishna S
Theranostics; 2021; 11(20):9752-9771. PubMed ID: 34815782
[No Abstract] [Full Text] [Related]
2. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity.
Winter GE; Radic B; Mayor-Ruiz C; Blomen VA; Trefzer C; Kandasamy RK; Huber KVM; Gridling M; Chen D; Klampfl T; Kralovics R; Kubicek S; Fernandez-Capetillo O; Brummelkamp TR; Superti-Furga G
Nat Chem Biol; 2014 Sep; 10(9):768-773. PubMed ID: 25064833
[TBL] [Abstract][Full Text] [Related]
3. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
[TBL] [Abstract][Full Text] [Related]
4. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.
Nyquist MD; Corella A; Burns J; Coleman I; Gao S; Tharakan R; Riggan L; Cai C; Corey E; Nelson PS; Mostaghel EA
Mol Cancer Res; 2017 May; 15(5):521-531. PubMed ID: 28465296
[TBL] [Abstract][Full Text] [Related]
5. Functional Investigation of Solute Carrier Family 35, Member F2, in Three Cellular Models of the Primate Blood-Brain Barrier.
Mochizuki T; Mizuno T; Kurosawa T; Yamaguchi T; Higuchi K; Tega Y; Nozaki Y; Kawabata K; Deguchi Y; Kusuhara H
Drug Metab Dispos; 2021 Jan; 49(1):3-11. PubMed ID: 33144341
[TBL] [Abstract][Full Text] [Related]
6. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
[TBL] [Abstract][Full Text] [Related]
7. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
Chiou JT; Chang LS
Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
[TBL] [Abstract][Full Text] [Related]
8. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.
Jung SA; Park YM; Hong SW; Moon JH; Shin JS; Lee HR; Ha SH; Lee DH; Kim JH; Kim SM; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Jin DH; Kim T
J Biol Chem; 2015 Apr; 290(16):9974-85. PubMed ID: 25635055
[TBL] [Abstract][Full Text] [Related]
9. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
Chiou JT; Lee YC; Huang CH; Wang LJ; Shi YJ; Chang LS
Biochem Pharmacol; 2021 Jun; 188():114544. PubMed ID: 33831396
[TBL] [Abstract][Full Text] [Related]
11. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
12. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
13. Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms.
Chen S; Chen X; Li Z; Mao J; Jiang W; Zhu Z; Li Y; Jiang Z; Zhao W; Tan G; Wang Z
Sci Rep; 2022 Apr; 12(1):6445. PubMed ID: 35440702
[TBL] [Abstract][Full Text] [Related]
14. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
Zhan T; Faehling V; Rauscher B; Betge J; Ebert MP; Boutros M
Int J Cancer; 2021 Apr; 148(8):1948-1963. PubMed ID: 33186476
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
Hu S; Fu S; Xu X; Chen L; Xu J; Li B; Qu Y; Yu H; Lu S; Li W
Cell Physiol Biochem; 2015; 37(3):1219-30. PubMed ID: 26418254
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
17. YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
Gyurászová K; Mikeš J; Halaburková A; Jendželovský R; Fedoročko P
Photochem Photobiol Sci; 2016 Jun; 15(6):812-21. PubMed ID: 27241169
[TBL] [Abstract][Full Text] [Related]
18. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
Zhang S; Wang X; Gu Z; Wang L
Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
[TBL] [Abstract][Full Text] [Related]
20. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.
Chang BH; Johnson K; LaTocha D; Rowley JS; Bryant J; Burke R; Smith RL; Loriaux M; Müschen M; Mullighan C; Druker BJ; Tyner JW
J Hematol Oncol; 2015 Apr; 8():39. PubMed ID: 25895498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
